drugset
drugset / Trial / NCT03046992

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

NCT03046992 ↗

Phase 1/2 Completed 224 enrolled Yuhan Corporation
NaSingle-groupOpen-labelTreatment

Summary

YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR. YH25448 is expected to beneficial for the NSCLC patients with brain metastasis due to good blood brain barrier (BBB) penetration property as well as for the treatment of primary lung lesion and extracranial lesions. This study will be conducted to evaluate the safety, tolerability and efficacy of YH25448 in locally advanced or metastatic NSCLC patients with EGFR mutations.

Timeline

Start
2017-02-15
Primary completion
2021-01-08
Completion
2023-03-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lazertinib Small molecule 20 mg Oral
Subject Lazertinib Small molecule 40 mg Oral
Subject Lazertinib Small molecule 80 mg Oral
Subject Lazertinib Small molecule 120 mg Oral
Subject Lazertinib Small molecule 160 mg Oral
Subject Lazertinib Small molecule 240 mg Oral
Subject Lazertinib Small molecule 320 mg Oral

Indications

No indication recorded.